NCT04113018View on ClinicalTrials.gov

Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 10, 2020

Primary Completion Date

June 28, 2023

Study Completion Date

October 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib, lenalidomide, dexamethasone (KRd) + Daratumumab

Experimental

Trial Locations (1)

28204

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (2)

Amgen
Celgene
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Celgene

INDUSTRY

collaborator

Janssen, LP

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER